LY2409021

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
02420142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
AIMS To evaluate whether treatment with LY2409021, a novel, selective glucagon receptor antagonist, is associated with changes in… (More)
  • table 1
  • figure 4
Is this relevant?
2017
2017
AIMS To assess the effect of LY2409021 on systolic blood pressure (SBP) in patients with type 2 diabetes. MATERIALS AND METHODS… (More)
Is this relevant?
2017
2017
The supplementary data originally attached to the article cited above was incorrect. The correct version of the supplementary… (More)
Is this relevant?
2016
2016
OBJECTIVE Type 2 diabetes pathophysiology is characterized by dysregulated glucagon secretion. LY2409021, a potent, selective… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
We appreciate the thoughtful comments raised by Agrawal and Gupta (1) on our recent article (2) on the efficacy and safety of the… (More)
Is this relevant?
2016
2016
Since the discovery of glucagon’s opposing actions to insulin, drugs targeting the inhibition of glucagon action have been… (More)
  • figure 1
Is this relevant?
2016
2016
We would like to congratulate Kazda et al. (1) for reporting the first phase 2 study of the glucagon receptor antagonist… (More)
Is this relevant?
2015
2015
AIM To describe the clinical effects of single and multiple doses of a potent, selective, orally administered, small-molecule… (More)
Is this relevant?
2015
2015
The first copper-catalyzed ring-opening electrophilic trifluoromethylation and trifluoromethylthiolation of cyclopropanols to… (More)
Is this relevant?
2014
2014
Interaction of the small peptide hormone glucagon with glucagon receptor (GCGR) stimulates the release of glucose from the… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?